혈우병 치료 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Global Hemophilia Treatment Market will exhibit a 5.6% CAGR between 2024 and 2032, driven by the increasing awareness and diagnosis of hemophilia, coupled with advancements in medical research and technology. The improved diagnostic techniques have led to early and more accurate identification of hemophilia, allowing for timely intervention and treatment.

Additionally, growing investment in research and development by pharmaceutical companies is fostering innovation in treatment options, propelling market expansion. Citing an instance, in May 2024, Sanofi, Formation Bio, and OpenAI announced a groundbreaking partnership to develop AI-driven software for faster drug development. This collaboration will integrate data, software, and custom models, marking a first-of-its-kind effort in pharma and life sciences. Enhanced healthcare infrastructure and increasing medical expenditure are contributing to the growth of the hemophilia treatment industry.

The overall market is categorized based on disease type, product, patient, drug class, treatment, route of administration, therapy, end-use, and region.

The hemophilia B segment will experience prominent expansion during the forecast period, attributed to heightened awareness and improved diagnostic capabilities. Additionally, the growing focus on personalized medicine and targeted therapies has driven advancements in treatment options specifically tailored for hemophilia B patients. Increased support for hemophilia research and the development of specialized treatment protocols are further amplifying the focus on this segment.

By 2032, the extended half-life products segment will achieve a prominent hemophilia treatment market share, owing to their ability to reduce the frequency of infusion required for effective disease management. This translates to improved patient convenience and adherence to treatment regimens. The extended half-life products also offer enhanced stability and efficacy, resulting in better overall management of hemophilia. The preference among patients and healthcare providers is boosting the demand for extended half-life products for hemophilia treatment.

From 2024 to 2032, the Europe hemophilia treatment industry will display an impressive growth graph, owing to the better healthcare infrastructure and access to advanced medical technologies. The strong focus on research and development, supported by substantial government and private investments, is fostering innovation in treatment options. Additionally, increasing awareness and early diagnosis of hemophilia are leading to a higher demand for effective treatments. The presence of favorable medical reimbursement policies is shaping the market outlook in Europe.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of hemophilia across the globe
    • 3.2.1.2 Rise in favorable government initiatives
    • 3.2.1.3 Increase in R and D and new product development
    • 3.2.1.4 Growing adoption of prophylaxis treatment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with hemophilia treatment
    • 3.2.2.2 Lack of awareness in developing and under-developed regions
    • 3.2.2.3 Low adoption rates of technologically advanced products
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Hemophilia A
  • 5.2.1 Severe
  • 5.2.2 Moderate
  • 5.2.3 Mild
• 5.3 Hemophilia B
  • 5.3.1 Severe
  • 5.3.2 Moderate
  • 5.3.3 Mild
• 5.4 Other disease types

Chapter 6 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Recombinant coagulation factor concentrates
  • 6.2.1 Factor VIII
  • 6.2.2 Factor IX
• 6.3 Plasma-derived coagulation factor concentrates
  • 6.3.1 Factor VIII
  • 6.3.2 Factor IX
• 6.4 Extended half-life products
  • 6.4.1 Factor VIII
  • 6.4.2 Factor IX
• 6.5 Desmopressin
• 6.6 Antifibrinolytic agents
• 6.7 Gene therapy products

Chapter 7 Market Estimates and Forecast, By Patient, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatric
  • 7.2.1. 0 to 4
  • 7.2.2. 5 to 13
  • 7.2.3. 14 to 18
• 7.3 Adult
  • 7.3.1. 19 to 44
  • 7.3.2. 45+

Chapter 8 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Prophylaxis
• 8.3 On demand

Chapter 9 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Factor replacement therapy
• 9.3 Non-factor replacement therapy

Chapter 10 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Vasopressin
• 10.3 Coagulation factors

Chapter 11 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 Injectable
• 11.3 Nasal spray
• 11.4 Oral

Chapter 12 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 12.1 Key trends
• 12.2 Hospitals
• 12.3 Clinics
• 12.4 Hemophilia treatment centers
• 12.5 Other end-users

Chapter 13 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 13.1 Key trends
• 13.2 North America
  • 13.2.1 U.S.
  • 13.2.2 Canada
• 13.3 Europe
  • 13.3.1 Germany
  • 13.3.2 UK
  • 13.3.3 France
  • 13.3.4 Spain
  • 13.3.5 Italy
  • 13.3.6 Netherlands
  • 13.3.7 Rest of Europe
• 13.4 Asia Pacific
  • 13.4.1 China
  • 13.4.2 Japan
  • 13.4.3 India
  • 13.4.4 Australia
  • 13.4.5 South Korea
  • 13.4.6 Rest of Asia Pacific
• 13.5 Latin America
  • 13.5.1 Brazil
  • 13.5.2 Mexico
  • 13.5.3 Rest of Latin America
• 13.6 Middle East and Africa
  • 13.6.1 South Africa
  • 13.6.2 Saudi Arabia
  • 13.6.3 UAE
  • 13.6.4 Rest of Middle East and Africa

Chapter 14 Company Profiles

• 14.1 Bayer AG
• 14.2 Biogen Inc.
• 14.3 Biotest AG (Grifols, S.A.)
• 14.4 BioMarin Pharmaceutical Inc
• 14.5 CSL Behring LLC
• 14.6 Ferring B.V.
• 14.7 Genentech, Inc. (Roche Holding AG)
• 14.8 Kedrion S.p.A
• 14.9 Novo Nordisk A/S
• 14.10 Octapharma AG
• 14.11 Pfizer, Inc.
• 14.12 Sanofi SA
• 14.13 Swedish Orphan Biovitrum AB
• 14.14 Takeda Pharmaceutical Company Limited